http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CO-6180441-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c539db959cc0106cab1662303f94fce |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-073 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-193 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-191 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| filingDate | 2009-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3aad4d8d70da181fbacc7ea55af519c2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11402a16cf6b2dcef3f9102d328f04f1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02b44c120b8fd035252bb1b1fee0f2c2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c920e68f54e9437665e3dadd4fe6d6d7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c015dd887dcdb4143c20d632d931ceb1 |
| publicationDate | 2010-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CO-6180441-A2 |
| titleOfInvention | HCV NUCLEOSID INHIBITORS |
| abstract | 1.- A compound of formula Idonde: R1, R2 and R3 are independently selected from the group consisting of hydrogen, COR4, C (= O) OR4 and C (= O) CHR5NHR6; or R1 and R3 are H and R2 is the monophosphate, diphosphate or triphosphate ester; R4 is independently selected from the group consisting of (a) C1-18 linear or branched alkyl, (b) C1-18 haloalkyl, (c) C3-8 cycloalkyl, (d) C1-10 heteroalkyl and (e) phenyl wherein said phenyl is optionally substituted with between one and three groups independently selected from C1-3 alkyl, C1-3 alkoxy, halogen, cyano or nitro; R5 is hydrogen, C1-10 alkyl, phenyl or C1-3 phenylalkyl wherein said phenyl is optionally substituted with between one and three groups independently selected from the group consisting of halogen, hydroxy, C1-3 alkoxy, C1-3 alkyl , cyano and nitro; R6 is hydrogen or C1-6 alkoxy; or, acid addition salts thereof. 2. A compound according to claim 1 wherein R1, R2 and R3 are in each case hydrogen. 3. A compound according to claim 1 wherein R1, R2 and R3 are each independently hydrogen, OCR4 or C (= O) OR4. 4. A compound according to claim 3 wherein R4 is C1-10 linear or branched alkyl. 5. A compound according to claim 1 wherein R1 is hydrogen and R2 and R3 are COR4. 6. A compound according to claim 1 wherein R1 is hydrogen, R2 and R3 are COR4 and R4 is linear or branched alkyl; or a pharmaceutically acceptable salt thereof. 7. A compound according to claim 1 wherein R1 and R3 are hydrogen R2 is selected from the group consisting of COR4, C (= O) OR4 and COCH (R5) NHR6. 8. A compound according to claim 7 wherein R2 is COCH (R5) NHR6, R5 is iso-propyl, iso-butyl or sec-butyl and R6 is hydrogen. 9. A compound according to claim 8 wherein R5 has the stereochemistry of an L-amino acid. 10. A compound according to claim 7, wherein R2 is OCR4. |
| priorityDate | 2006-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.